Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
51 hedge funds and large institutions have $18.4M invested in Vincerx Pharma, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 22 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 15
24% less funds holding
Funds holding: 67 → 51 (-16)
64% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 22
72% less capital invested
Capital invested by funds: $65.1M → $18.4M (-$46.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
+$1.22M |
| 2 |
Millennium Management
New York
|
+$579K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$385K |
| 4 |
Renaissance Technologies
New York
|
+$380K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$223K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$5.52M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.44M |
| 3 |
BlackRock
New York
|
-$1.4M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$906K |
| 5 |
State Street
Boston,
Massachusetts
|
-$348K |
VINC Hedge Fund Activity: Q2 2022 in Review
51 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q2 2022, worth a combined $18.4M — down 72% from $65.1M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of VINC and 8 opened new positions — a net loss of 14 holders — while 15 trimmed existing stakes and 15 added.
The largest buyer was Long Focus Capital Management, adding an estimated $1.22M. The largest seller was Deerfield Management, exiting entirely with an estimated $5.52M sold.
- 51 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q2 2022, down from 67 in Q1 2022.
- Funds reported $18.4M of Vincerx Pharma, Inc. Common Stock stock for Q2 2022, down 72% quarter-over-quarter.
- 8 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q2 2022 and 22 closed out, a net change of -14 holders.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q2 2022 was Long Focus Capital Management, an estimated $1.22M added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q2 2022 was Deerfield Management, an estimated $5.52M sold.
Based on aggregated 13F filings for Q2 2022.